Accelerant Shares Rose 43.35% After Thoma Bravo Agreed to Pay $20.25 Cash

Deal announcement drove the repricing

Accelerant Holdings shares closed at $19.51 on August 13, 2026, up $5.90, or 43.35%, from the prior close of $13.61. The move followed Accelerant’s agreement to be acquired by affiliates of Thoma Bravo Discover Fund V for $20.25 in cash for each Class A or Class B share. The companies described the transaction as having an enterprise value of more than $4 billion in their joint announcement.

ARX traded between $19.45 and $19.62 and recorded volume of 70,080,006 shares, compared with 2,200,360 shares on August 12, according to Stock Analysis price history. The closing price sat $0.74, or about 3.65%, below the stated base cash consideration.

The offer represented a stated 49% premium to the August 12 closing price. The rapid move toward $20.25 and the increase in volume are consistent with a merger-arbitrage repricing. Accelerant also reported second-quarter results, which provide operating context for the negotiated valuation, but the available information cannot isolate how much of the daily gain came from those results versus the acquisition agreement.

The $20.25 consideration was below Accelerant’s July 2025 IPO price of $21.00. It was approximately 3.6% below that IPO price while remaining substantially above the unaffected August 12 close. Accelerant disclosed the IPO price in its July 2025 offering announcement.

Transaction terms and shareholder support

Accelerant signed the merger agreement with Cherry Tree BidCo and Cherry Tree Merger Sub, Thoma Bravo affiliates. Accelerant’s independent and disinterested Special Committee, chaired by Karen Meriwether, unanimously recommended the transaction, and the full board unanimously approved it.

Altamont Capital Partners affiliates ACP Insurance Management and ACP Accelerant Holdings, which control about 82% of Accelerant’s outstanding voting rights, agreed to support the merger. Shareholder approval requires at least two-thirds of votes cast. That support makes failure at the shareholder-vote stage less likely if the agreement remains effective, though it does not ensure completion.

The merger has no financing condition. Thoma Bravo Discover Fund V provided an equity commitment intended to cover the cash consideration, any applicable ticking amount, relevant expenses, and certain debt repayment. The August 13 Form 8-K details those commitments and other transaction terms.

If the merger closes, ARX will be delisted from the New York Stock Exchange and Accelerant will become a privately held subsidiary of the Thoma Bravo acquisition entity. The fixed cash payment shifts the principal valuation reference from Accelerant’s public-market earnings outlook to the conditional merger consideration.

Closing conditions and remaining uncertainty

The companies expect the transaction to close in the first half of 2027. Closing remains subject to antitrust, foreign-investment, and specified insurance-regulatory approvals; the absence of a continuing material adverse effect; and dissent rights exercised for no more than 15% of outstanding shares. The initial outside date is August 13, 2027, with a potential extension to November 13, 2027 under specified regulatory circumstances, according to the merger agreement.

The $0.74 trading spread can reflect time to closing, transaction costs, closing risk, and regulatory uncertainty. It does not establish a specific market assessment of insurance-regulatory approval. The agreement also includes a conditional ticking amount linked to specified insurance-regulatory delays after other defined conditions are met. The amount is not guaranteed solely because closing takes time.

Accelerant may seek proposals from specified eligible parties through September 22, 2026. A qualifying superior proposal from an eligible go-shop party would carry a $56.9 million termination fee, compared with a $136.5 million fee in certain other termination cases. The parent termination fee is $295.8 million. Whether the go-shop produces another proposal remains unknown.

Altamont and Accelerant’s founders stated an intention to retain equity, but the August 13 8-K said Altamont had made no binding rollover or reinvestment commitment. The forthcoming proxy statement and any Schedule 13E-3 are expected to provide further information on the sale process, projections, fairness analyses, conflicts, and transaction-related interests.

MacroShed Markets is informational analysis, not investment advice.